Valeant Pharmaceuticals (NYSE:VRX)‘s stock had its “conviction-buy” rating reaffirmed by Goldman Sachs Group Inc. in a research note issued on Thursday, AnalystRatingsNetwork.com reports. They currently have a $130.00 target price on the stock. Goldman Sachs Group Inc.’s target price would suggest a potential upside of 19.20% from the company’s current price.
Valeant Pharmaceuticals (NYSE:VRX) traded down 2.20% on Thursday, hitting $106.66. The stock had a trading volume of 3,615,611 shares. Valeant Pharmaceuticals has a 1-year low of $50.74 and a 1-year high of $105.40. The stock has a 50-day moving average of $107.5 and a 200-day moving average of $92.72. The company’s market cap is $35.574 billion.
Valeant Pharmaceuticals (NYSE:VRX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.51 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.40 by $0.11. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $884.14 million. During the same quarter in the prior year, the company posted $1.15 earnings per share. The company’s quarterly revenue was up 74.4% on a year-over-year basis. On average, analysts predict that Valeant Pharmaceuticals will post $6.14 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at FBR Capital Markets initiated coverage on shares of Valeant Pharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating and a $130.00 price target on the stock. Separately, analysts at Aegis reiterated a “positive” rating on shares of Valeant Pharmaceuticals in a research note to investors on Monday. Finally, analysts at Zacks upgraded shares of Valeant Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, October 8th. They now have a $112.40 price target on the stock. One equities research analyst has rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $113.83.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.